Lates News

Medical research and drug development company Sarepta Therapeutics Inc. fell by more than 13.66% at one point, leading to a cumulative decline of over 20.96% in the past five trading days. An advisory committee of the European Medicines Agency has recommended against approving the company's gene therapy Elevidys.